Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Bioconjugate Pneumococcal Vaccine in Healthy Adults
NCT03303976Phase 1Completed
- Sponsor
- LimmaTech Biologics
- Start
- Sep 2017
- Primary completion
- Sep 2018
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised trial of pneumococcal conjugate vaccine in Pneumococcal pneumonia (PP) and bacterial pneumonia (4 arms), sponsored by LimmaTech Biologics. Primary endpoint: Incidence of adverse events at 1 month. Started Sep 2017; status: completed.
02
Drugs
pneumococcal conjugate vaccine
03
Conditions
Pneumococcal pneumonia (PP)bacterial pneumonia
Beyond the preview
Go deeper on NCT03303976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03303976.